Arthritis News and Research

Latest Arthritis News and Research

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Anthera reports increase in second quarter total operating expenses to $22.7 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the quarter ended June 30, 2011.

29 Jul 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

AARDA develops a plan to calculate one's own Autoimmune Quotient

Hollywood bombshell Kim Kardashian recently shared her diagnosis of the autoimmune disease psoriasis on her E! reality TV series, "Keeping Up With The Kardashians."

29 Jul 2011

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

Hip and knee replacement surgery linked to increased risk of clot development

When tennis star Serena Williams underwent emergency treatment for a pulmonary embolism earlier this year, the world's attention was drawn to this often fatal medical condition which, although surprisingly not uncommon, is unfamiliar to most men and women.

28 Jul 2011

New study shows high prevalence of gout in the U.S.

A new study shows the prevalence of gout in the U.S. has risen over the last twenty years and now affects 8.3 million (4%) Americans.

28 Jul 2011

Male sex hormones can protect men from inflammatory diseases

It's all down to the testosterone: men are usually more muscular than women, they have deeper voices and more body hair. And - men are less susceptible to inflammatory diseases and allergies than women. This is also due to the male sex hormones as pharmacists at the Friedrich Schiller University Jena have shown in a recent study.

27 Jul 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

Illinois Bone and Joint Institute upgrades to High Field Open MRI System

Illinois Bone and Joint Institute, MRI Services, is proud to announce the installation of the first High Field Open MRI serving patients of Chicago and Northeastern Illinois.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Blue-collar workers with arthritis in much worse health than all other workers

While more Americans are working past age 65 by choice, a growing segment of the population must continue to work well into their sixties out of financial necessity. Research conducted by the Columbia University's Mailman School of Public Health and the University of Miami Miller School of Medicine looked at aging, social class and labor force participation rates to illustrate the challenges that lower income workers face in the global marketplace.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

High cost of multiple sclerosis drugs

According to a study released this Wednesday, drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost.

21 Jul 2011

U.S. physicians to receive nearly $10M from Humana's Provider Quality Rewards Program

Humana Inc. has begun distributing nearly $10 million to physicians across the U.S. who participate in Humana's Provider Quality Rewards Program. Approximately 2,800 physician practices will receive payments of as much as $175,000 in recognition of performance improvements their practices made during 2010 related to improved outcomes for Humana's Medicare members.

21 Jul 2011

Dealing with chronic pain

For people with severe chronic pain like Kelly Young and Teresa Shaffer—both of whom have become patient advocates —coping with agony is a fact of life. Young suffers from rheumatoid arthritis while Shaffer's pain is linked primarily to another degenerative bone disease.

21 Jul 2011

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.

20 Jul 2011